Answers are grounded in this paper and cite their sources.
The rising incidence of monkeypox, a DNA virus-driven infectious disease, highlights the urgent need for effective interventions. While disease severity varies among patients, similarities to smallpox suggest potential overlaps in treatment approaches. Researchers have focused on thymidylate kinase (TMPK) inhibitors, which play a critical role in activating DNA precursors. By targeting this mechanism, viral replication can be halted, rendering the virus inactive. Using computational methods, including molecular docking analysis, we assessed potential inhibitors by predicting their binding affinity to the TMPK enzyme. Tecovirimat emerged as a promising candidate, demonstrating a strong affinity for TMPK. Additionally, Compound 25c showed superior binding affinity and stability in molecular dynamics simulations, making it a particularly interesting candidate for further exploration. These findings suggest that Tecovirimat analogs, including Compound 25c, could potentially suppress TMPK activity in the monkeypox virus. However, comprehensive experimental studies are essential to confirm the efficacy of these analogs as viable treatments, further illuminating their therapeutic potential in combating this infectious disease.
No takes yet. Share an insight, caveat, or question.
Khater et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: